
    
      Subjects will undergo a Screening period beginning up to 28 days prior to randomisation, the
      first of two vaccinations administered 2 months apart, pre- and post-dose assessment,
      follow-up visits, and an end of study (EOS) or early termination (ET) visit (as applicable).

      Subjects will be randomised prior to vaccination on Day 1, to one (1) of five (5) treatment
      groups.
    
  